Compare MobilEye Global Inc (MBLY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Smith & Nephew plc — how do they compare? MobilEye Global Inc trades at $7.21 (market cap $6.00B), while Smith & Nephew plc trades at $27.05 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Smith & Nephew plc for 120 Days on average.
| MBLY | SNN | |
|---|---|---|
Market Cap | $6.00B | $11.10B |
Volume | 7,007,849 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $37.17 |
52-Week Low | $6.56 | $26.42 |
Typical Hold Time | 15 Days | 120 Days |
Enterprise Value | $4.56B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.14, down 0.14% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $2.0B in 2026 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus is mixed with 57.7% buy ratings but a bearish technical outlook from indicators.
The stock presents a high-risk opportunity with substantial upside to the $10.83 consensus target but requires careful monitoring of profitability improvements. Key risks include persistent losses, competitive pressures in autonomous driving, and execution challenges in robotaxi expansion.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
